Can risk-adapted treatment recommendations replace the 'one size fits all' approach for early-stage thyroid cancer patients?
Oncology (Williston Park)
.
2009 Jun;23(7):592, 600, 603.
Authors
R Michael Tuttle
1
,
James A Fagin
Affiliation
1
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
PMID:
19626825
No abstract available
Publication types
Comment
MeSH terms
Combined Modality Therapy
Humans
Neoplasm Staging
Risk Factors
Thyroid Neoplasms / pathology
Thyroid Neoplasms / therapy*